BACKGROUND: Approximately 30% of all colorectal cancer patients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well-established that a subgroup of patients with stage II is at high risk for recurrence within their life time and should be considered for adjuvant chemotherapy. The present work was designed to assess the value of matrix metalloproteinase-9 (MMP-9) as a predictor of disease outcome in a series of 202 stage II colorectal cancer (CRC) patients with long-term follow-up. METHODS: The present study comprises a series of 202 patients who underwent bowel resection for stage II CRC at Turku University Hospital. Archival paraffin-embedded CRC tissue samples were used to prepare tissue microarray blocks for immunohistochemical staining with MMP-9 antibody. RESULTS: Forty-eight percent of all CRC samples were positive for MMP-9. There was no significant correlation between MMP-9 expression and age, depth of invasion, and lymph node status. However, MMP-9 expression was significantly related to histological grade (p = 0.03) and location of the tumor (p = 0.01), therefore, being lower in high-grade tumors and most intense in carcinomas of the descending colon and rectum. Tumors with high MMP-9 expression showed a higher recurrence rate than tumors with low expression (p = 0.02). MMP-9 negative tumors had a more favorable disease-free survival (DFS) than those expressing MMP-9 (p = 0.03). The same was true with disease-specific survival (DSS; p = 0.02) as well, high expression of MMP-9 being associated with shorter survival rates. In multivariate (Cox) survival analysis, MMP-9 expression proved to be an independent predictor of DFS, but not DSS, which was predicted by age and sex only. CONCLUSION: Quantification of MMP-9 expression seems to provide valuable prognostic information in stage II CRC, particularly, in selecting the patients at high risk for recurrent disease who might benefit from adjuvant therapy.
BACKGROUND: Approximately 30% of all colorectal cancerpatients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well-established that a subgroup of patients with stage II is at high risk for recurrence within their life time and should be considered for adjuvant chemotherapy. The present work was designed to assess the value of matrix metalloproteinase-9 (MMP-9) as a predictor of disease outcome in a series of 202 stage II colorectal cancer (CRC) patients with long-term follow-up. METHODS: The present study comprises a series of 202 patients who underwent bowel resection for stage II CRC at Turku University Hospital. Archival paraffin-embedded CRC tissue samples were used to prepare tissue microarray blocks for immunohistochemical staining with MMP-9 antibody. RESULTS: Forty-eight percent of all CRC samples were positive for MMP-9. There was no significant correlation between MMP-9 expression and age, depth of invasion, and lymph node status. However, MMP-9 expression was significantly related to histological grade (p = 0.03) and location of the tumor (p = 0.01), therefore, being lower in high-grade tumors and most intense in carcinomas of the descending colon and rectum. Tumors with high MMP-9 expression showed a higher recurrence rate than tumors with low expression (p = 0.02). MMP-9 negative tumors had a more favorable disease-free survival (DFS) than those expressing MMP-9 (p = 0.03). The same was true with disease-specific survival (DSS; p = 0.02) as well, high expression of MMP-9 being associated with shorter survival rates. In multivariate (Cox) survival analysis, MMP-9 expression proved to be an independent predictor of DFS, but not DSS, which was predicted by age and sex only. CONCLUSION: Quantification of MMP-9 expression seems to provide valuable prognostic information in stage II CRC, particularly, in selecting the patients at high risk for recurrent disease who might benefit from adjuvant therapy.
Authors: C S Fuchs; E L Giovannucci; G A Colditz; D J Hunter; M J Stampfer; B Rosner; F E Speizer; W C Willett Journal: N Engl J Med Date: 1999-01-21 Impact factor: 91.245
Authors: László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay Journal: Pathol Oncol Res Date: 2008-03-18 Impact factor: 3.201
Authors: C F Sier; F J Kubben; S Ganesh; M M Heerding; G Griffioen; R Hanemaaijer; J H van Krieken; C B Lamers; H W Verspaget Journal: Br J Cancer Date: 1996-08 Impact factor: 7.640
Authors: László Herszényi; Fabio Farinati; Romilda Cardin; Gábor István; László D Molnár; István Hritz; Massimo De Paoli; Mario Plebani; Zsolt Tulassay Journal: BMC Cancer Date: 2008-07-10 Impact factor: 4.430
Authors: Eni M Souza; Otávio C G Baiocchi; Maria A Zanichelli; Antonio C Alves; Marianne G Assis; Joyce M K Silva; Cristine Dobo; José S R Oliveira Journal: Med Oncol Date: 2011-09-16 Impact factor: 3.064
Authors: Graciele Almeida de Oliveira; Robert Y S Cheng; Lisa A Ridnour; Debashree Basudhar; Veena Somasundaram; Daniel W McVicar; Hugo Pequeno Monteiro; David A Wink Journal: Antioxid Redox Signal Date: 2016-10-31 Impact factor: 8.401
Authors: Adam Elzagheid; Fatma Emaetig; Abdelbaset Buhmeida; Matti Laato; Omran El-Faitori; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen Journal: Tumour Biol Date: 2012-11-21
Authors: László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay Journal: World J Gastroenterol Date: 2014-10-07 Impact factor: 5.742
Authors: Derek C Marshall; Susan K Lyman; Scott McCauley; Maria Kovalenko; Rhyannon Spangler; Chian Liu; Michael Lee; Christopher O'Sullivan; Vivian Barry-Hamilton; Haben Ghermazien; Amanda Mikels-Vigdal; Carlos A Garcia; Brett Jorgensen; Arleene C Velayo; Ruth Wang; Joanne I Adamkewicz; Victoria Smith Journal: PLoS One Date: 2015-05-11 Impact factor: 3.240
Authors: Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston Journal: Clin Cancer Res Date: 2012-08-02 Impact factor: 12.531
Authors: László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay Journal: Int J Mol Sci Date: 2012-10-16 Impact factor: 5.923